In NSCLC, FOXC1 knockdown increased cisplatin and docetaxel sensitivity and reduced gefitinib resistance, whereas FOXC1 overexpression enhanced CSC-like properties and resistance to cisplatin and docetaxel (56). Here, FOXC1 is linked to non-small cell lung carcinoma.